UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023524
Receipt number R000027082
Scientific Title Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients
Date of disclosure of the study information 2016/08/08
Last modified on 2020/08/14 11:03:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients

Acronym

PD-L1 expression in immune cells and soluble PD-L1 in gastrointestinal cancer patients

Scientific Title

Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients

Scientific Title:Acronym

PD-L1 expression in immune cells and soluble PD-L1 in gastrointestinal cancer patients

Region

Japan


Condition

Condition

Gastrointestinal Cancer
(Esophagial cancer,Gastric cancer, pancreatic cancer, liver cancer,billiary tract cancer, colorectal cancer)

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

PD-L1 expression in immune cells and soluble PD-L1 value in blood of various gastrointestinal cancer patients will be examined and their association with clinicopathological features of the diseases will be elucidated.

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Correlation between PD-L1 expression in immune cells and soluble PD-L1 value.
Correlation between PD-L1 expression in immune cells or soluble PD-L1 value and PD-L1 expression in tumor tissue.
Characterstics of PD-L1 expression in immune cells or soluble PD-L1 value in each gastrointestinal cancer type.

Key secondary outcomes

PD-L1 expression in immune cells or blood soluble PD-L1 value as a new biomarker for specific clinico-pathological features in gastrointestinal cancers.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients diagnosed as esophagial cancer, gastric cancer, pancreatic cancer, billiary tract cancer, or colorectal cancer.
Patients who have agreed to provide their blood for this study.

Key exclusion criteria

Patients who have not agreed to provide their blood for this study.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name SADAMU
Middle name
Last name HOMMA

Organization

Jikei University School of Medicine

Division name

Division of Oncology

Zip code

105-8461

Address

3-25-8 Nishi-shimbashi Minato-ku, Tokyo 105-8461 Japan

TEL

03-3433-1111

Email

sahya@jikei.ac.jp


Public contact

Name of contact person

1st name Sadamu
Middle name
Last name SADAMU HOMMA

Organization

Jikei University School of Medicine

Division name

Division of Oncology

Zip code

105-8461

Address

3-25-8 Nishi-shimbashi Minato-ku, Tokyo 105-8461 Japan

TEL

03-3433-1111

Homepage URL


Email

sahya@jikei.ac.jp


Sponsor or person

Institute

Jikei University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Jikei University School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Jikei University IRB

Address

3-25-8 Nishi-shimbashi Minato-ku

Tel

+81334331111

Email

sahya@jikei.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 08 Month 08 Day


Related information

URL releasing protocol

none

Publication of results

Unpublished


Result

URL related to results and publications

none

Number of participants that the trial has enrolled

85

Results

No results to be disclosed were obtained.

Results date posted

2020 Year 08 Month 14 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Patients of gastrointestinal(GI) cancer in Jikei University Hospital

Participant flow

Patients of GI cancer in Jikei University Hospital with agreement for the study were enrolled.

Adverse events

none

Outcome measures

Expression of PD-L1 in the immune cells, blood levels of sPD-L1 and the association between the above two in the patients of GI cancer.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 05 Month 31 Day

Date of IRB

2016 Year 06 Month 14 Day

Anticipated trial start date

2016 Year 08 Month 01 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

PD-L1 expression in peripheral blood mononuclear cells will be examined by FACS, and amount of soluble PD-L1 in the patient blood will be determined by ELISA.Correlation of these results and the clinico-pathological features of the patients will be analyzed.


Management information

Registered date

2016 Year 08 Month 06 Day

Last modified on

2020 Year 08 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027082


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name